Chicago-based Paragon Biosciences LLC has launched its seventh portfolio company, Qlarity Imaging LLC, which will focus on further developing Quantx, an FDA-cleared, computer-aided breast cancer diagnosis system.
Johnson & Johnson (J&J), of New Brunswick, N.J., soared in its second quarter, with pharmaceuticals leading the way. While pharma took top billing, devices beat what had been forecast, with worldwide sales of $6.49 billion. That figure came above the $6.43 billion consensus, as Cowen's Joshua Jennings noted.
With an eye toward helping patients with chronic kidney disease (CKD) receive earlier interventions, Fresenius Medical Care North America (FMCNA) has made an investment in Biointellisense Inc., of Denver. Biointellisense is developing a medical grade data services platform for continuous health monitoring, predictive analytics and algorithmic clinical insights.
Mountain View, Calif.-based Neuropace Inc. is looking to take on a new challenge with its closed-loop neuromodulation technology. To that end, a study will examine whether its responsive neurostimulation (RNS) system could help in managing loss-of-control eating in patients with a body mass index of 45-60 kg/m2 for whom medication and gastric bypass surgery have not proven effective.
Paris-based Ablacare SA, which is focused on women's health and fertility care, has raised €10 million (US$11.2 million) in series A financing from Sofinnova Partners. Proceeds are earmarked for advancing the company's clinical and regulatory programs in Europe and the U.S. The company also reported the appointment of medical device executive Jodie Fam as CEO. In addition, Andrew Weiss, president and CEO at Recor Medical Inc., has been named chairman of the company's board.
